TPM3 and renal cell carcinoma: The comprehensive analysis of TPM3 gene fusions presented in this review underscores their significant role as oncogenic drivers across a diverse spectrum of malignancies including inflammatory myofibroblastic tumors, anaplastic large cell lymphoma, renal cell carcinoma, colorectal cancer, thyroid carcinoma, non‐small cell lung cancer, soft tissue sarcomas, and glioma.